Adar Poonawalla

The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year.

China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.

Vaccine maker Serum Institute of India CEO Adar Poonawalla has called for global harmonisation or regulatory standards and said that cooperation among multilateral organisations is a must for dealing with future outbreaks.

The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.

Serum Institute of India CEO Adar Poonawalla on Sunday praised India's fight against the Covid pandemic, saying the government and the healthcare workers contributed largely to tackling the pandemic in the country.

Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.

Raising concern on the rising COVID-19 cases in neighbouring China, Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday asked the people not to panic because of India's "excellent vaccination coverage and track record".

In a major breakthrough, the Pune Police said today that they have arrested seven accused in the cheating case in which Serum Institute of India (SII) was cheated of over Rs 1.01 crore.

Seven people have been arrested for allegedly using the image of Serum Institute of India CEO Adar Poonawalla and getting a director of the leading vaccine-producing firm to transfer Rs 1.01 crore to various bank accounts, Pune police said on Friday.

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said.

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.

The Serum Institute of India will try to launch Omicron-specific vaccine for COVID-19 after six months, its CEO Adar Poonawalla said on Thursday.

The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year.

China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.

Vaccine maker Serum Institute of India CEO Adar Poonawalla has called for global harmonisation or regulatory standards and said that cooperation among multilateral organisations is a must for dealing with future outbreaks.

The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.

Serum Institute of India CEO Adar Poonawalla on Sunday praised India's fight against the Covid pandemic, saying the government and the healthcare workers contributed largely to tackling the pandemic in the country.

Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.

Raising concern on the rising COVID-19 cases in neighbouring China, Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday asked the people not to panic because of India's "excellent vaccination coverage and track record".

In a major breakthrough, the Pune Police said today that they have arrested seven accused in the cheating case in which Serum Institute of India (SII) was cheated of over Rs 1.01 crore.

Seven people have been arrested for allegedly using the image of Serum Institute of India CEO Adar Poonawalla and getting a director of the leading vaccine-producing firm to transfer Rs 1.01 crore to various bank accounts, Pune police said on Friday.

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023, a top official has said.

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.

The Serum Institute of India will try to launch Omicron-specific vaccine for COVID-19 after six months, its CEO Adar Poonawalla said on Thursday.